Impact of Hepatitis C Virus Eradication on the Clinical Outcome of Patients with Hepatitis C Virus-Related Advanced Hepatocellular Carcinoma Treated with Sorafenib
| Autor: | Masataka Tsuge, Michio Imamura, Fumi Honda, Yuko Nagaoki, Yoshiiku Kawakami, Kei Morio, Yuji Teraoka, Kazuaki Chayama, Tomokazu Kawaoka, Reona Morio, Tomoki Kobayashi, Takashi Nakahara, Yuki Inagaki, Akira Hiramatsu, Masahiro Hatooka, Hiroshi Aikata |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Male
Niacinamide Sorafenib Cancer Research medicine.medical_specialty Carcinoma Hepatocellular Hepatitis C virus Antineoplastic Agents Hepacivirus macromolecular substances medicine.disease_cause Antiviral Agents Gastroenterology Disease-Free Survival Time-to-Treatment 03 medical and health sciences 0302 clinical medicine Japan Internal medicine medicine Humans Sustained viral response Aged Retrospective Studies Aged 80 and over business.industry Phenylurea Compounds Liver Neoplasms virus diseases General Medicine Hepatitis C Chronic Middle Aged medicine.disease digestive system diseases Treatment Outcome Oncology 030220 oncology & carcinogenesis Hepatocellular carcinoma Disease Progression Female 030211 gastroenterology & hepatology business medicine.drug |
| Zdroj: | Oncology. 92:335-346 |
| ISSN: | 1423-0232 0030-2414 |
| Popis: | Objective: To evaluate the impact of hepatitis C virus (HCV) eradication on the clinical outcome of patients with HCV-related advanced hepatocellular carcinoma (HCC) treated with sorafenib. Methods: A total of 58 HCV-related advanced HCC patients with Child-Pugh grade A disease who were treated with sorafenib were enrolled in this retrospective cohort study. Of these, 27 patients were HCV RNA negative as a result of previous antiviral therapy (sustained viral response [SVR] group), while the remaining 31 were HCV RNA positive (non-SVR group). Results: The response rate, disease control rate and median time to progression in the SVR group (6, 46.0%, and 3.8 months, respectively) were similar to those in the non-SVR group (3, 51.5%, and 2.7 months, respectively). On the other hand, the median time to treatment failure (TTTF), post-progression survival (PPS), and overall survival (OS) were significantly longer in the SVR group than in the non-SVR group (9.7, 8.5, and 15 months vs. 5.9, 5.2, and 9.3 months; p = 0.023, 0.02, and 0.014, respectively). On multivariate analysis, SVR was identified as a significant and independent determinant of PPS (p = 0.009), TTTF (p = 0.028), and OS (p = 0.01). Conclusion: HCV eradication before sorafenib treatment for HCV-related advanced HCC could prolong PPS and TTTF and improve OS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|